This is my last question.
Do you think this agency, CDR, can actually expand its mandate and recommend how long the drug should be protected under patent? If you make that recommendation, then—I'm thinking completely outside the box—the generics would be able to come in sooner, perhaps, therefore lowering the cost of some of these very expensive drugs. Is that a role this agency could play, possibly?